☰

Cerbios-Pharma SA

Coordinating three Swiss CDMO sites around a shared data model

Industry
Pharmaceutical CDMO (HPAPIs, ADCs, biologics)
Headquarters
Barbengo-Lugano, Switzerland
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Cerbios-Pharma SA's published strategy and is not endorsed by, or produced in cooperation with, Cerbios-Pharma SA. Company website

Strategic priorities

Cerbios-Pharma is part of the HAS Healthcare Advanced Synthesis Group, formed by the May 2025 acquisition that brought together Cerbios-Pharma in Barbengo-Lugano, GMT Fine Chemicals in Couvet and HAS Healthcare Advanced Synthesis in Biasca. The acquisition was supported by 65 Equity Partners, which holds approximately 40 percent of the post-acquisition entity, and the HAS Group has framed 2026 as the year its Investment Plan moves from announcement to execution.

The technical centre of gravity is HPAPI (High Potency Active Pharmaceutical Ingredient) and ADC (Antibody-Drug Conjugate) manufacturing at SafeBridge Category 4 containment, with occupational exposure limits below 10 nanograms per cubic metre. The February 2025 Lugano expansion added high- and low-pressure chromatography, nanofiltration and freeze-drying to a clinical and commercial HPAPI footprint, and the ADC pipeline of more than 260 candidates in clinical trials is the demand driver behind the Investments Plan 2026 announced on 13 January 2026.

Inside Category 4 units, operators interact with equipment through isolator gloves and cannot reach a keyboard or terminal without breaking containment, so the route to continuous process data has to be non-intrusive. The PROVEO alliance with AGC Biologics (monoclonal antibody production) and Oncotec (aseptic fill and finish) is a tri-party ADC programme coordinated by project management rather than by shared systems, and a 525 kWp photovoltaic installation at the Lugano site provides around ten percent of site energy without yet being tied back to specific manufacturing batches.

Cerbios has maintained an exemplary inspection record across FDA, Swissmedic, PMDA and EMA for more than twenty years, with no Form 483 observations in the April 2018 FDA general cGMP (current Good Manufacturing Practice) inspection. The next phase of growth under the Investments Plan 2026 extends the same quality posture into a multi-site, multi-partner operation, which puts shared data and electronic records squarely on the critical path.

Challenges we see

  • Operations Manufacturing

    Reaching process data inside Category 4 containment

    SafeBridge Category 4 containment at occupational exposure limits below 10 ng/m³ requires full isolator operation; the 2025 Lugano expansion added nanofiltration and freeze-drying units, both of which depend on tightly held pressure and temperature setpoints.

    Where data is read by hand from a local display, the population under review is the entire batch history, not the batch currently in front of the operator. Capturing the process signal at the equipment lets the population narrow to the units whose parameters actually deviated.

  • Digital Integration

    Bringing three Swiss sites onto one operating picture

    The HAS Group combines Cerbios-Pharma in Lugano, GMT Fine Chemicals in Couvet and HAS Healthcare Advanced Synthesis in Biasca, each with its own ERP (Enterprise Resource Planning) and LIMS (Laboratory Information Management System) heritage; group-level reporting today depends on extracts rather than a shared model.

    Decisions taken across three sites become a question of which source is authoritative at a given moment. A shared model turns the question from reconciliation into a query.

  • Operations Manufacturing

    Shortening ADC characterisation cycles without losing depth

    ADC characterisation pulls data from a 400 MHz NMR (Nuclear Magnetic Resonance spectrometer), an HR-Q-TOF (High-Resolution Quadrupole Time-of-Flight) mass spectrometer, DSC (Differential Scanning Calorimetry) and multiple UPLC (Ultra-Performance Liquid Chromatography) systems, with results compiled into regulatory packages by hand.

    Where scientists spend the working day stitching numbers into a document, the analytical answer is late by definition. Returning the instrument outputs as structured data leaves the scientist's time for the interpretation the work actually requires.

  • Operations Supply

    Making PROVEO a coordinated alliance rather than three separate projects

    The PROVEO ADC alliance with AGC Biologics and Oncotec is currently run as a coordinated project across three companies with three ERP systems and shared spreadsheets; the monoclonal antibody, linker, payload and conjugate steps are tracked manually.

    When the status of an upstream component is only known at a scheduled meeting, the time available to adjust a downstream step is bounded by the meeting cadence. A shared view of the same numbers turns adjustment into a continuous activity.

  • Compliance Regulatory

    Keeping ALCOA+ evidence intact across a growing operation

    Cerbios has passed FDA, Swissmedic, PMDA and EMA inspections for more than twenty years without Form 483 observations; the QA/DRA (Quality Assurance / Regulatory Affairs) and Qualified Person team is the named owner of that record and operates with manual logs, signatures and Excel-based records.

    As production volume grows, the human bridge between the shop floor and the regulatory submission is asked to carry more transfers per release. Moving that bridge onto a system with its own audit trail keeps the same evidence under a larger workload.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Reading Category 4 process signals without entering containment

    HPAPI reactors, nanofiltration and freeze-drying units in SafeBridge Category 4 isolators are physically sealed, so process data is either trapped inside the equipment or captured by hand when an operator pauses to read a local display.

    Adding non-intrusive OPC UA (Open Platform Communications Unified Architecture) sensors and a streaming pipeline lets pressure, temperature and flow be observed at the line in real time, so deviation alerts reach the control room without anyone entering the isolator.

    • Cerbios-Pharma S.A. Boosts Production Capabilities for HPAPIs and ADCs, 2025
    • HAS Healthcare Advanced Synthesis Investments Plan 2026, 13 January 2026

  2. One data model across the HAS Group's three Swiss sites

    Cerbios-Pharma in Lugano, GMT Fine Chemicals in Couvet and HAS Healthcare Advanced Synthesis in Biasca carry separate ERP and LIMS systems, so capacity, inventory and financial reporting are built from per-site extracts rather than a shared view.

    An ontology-based group data platform defines capacity, batch, lot and equipment as shared entities and loads each site's data against them, giving the CEO/CFO and 65 Equity Partners the same numbers without per-site reconciliation.

    • The HAS Group — Cerbios-Pharma SA, Barbengo-Lugano — Couvet — Switzerland
    • Cerbios-Pharma SA Company Overview, IntuitionLabs

  3. Returning hours to ADC characterisation

    ADC batch release pulls results from NMR, HR-Q-TOF, DSC and UPLC systems into regulatory packages by hand, and the same scientists are the ones expected to extend the characterisation as new payloads and linkers enter the pipeline.

    Ingesting each instrument's output into one analytical data layer, with sample and result mapped to a shared ontology, lets a release package be assembled from the data rather than retyped, and frees scientist time for the interpretation that actually needs a person.

    • Cerbios-Pharma SA, Moving along with ADCs: a CDMO perspective
    • Cerbios-Pharma SA, 247 Biopharma Interview with Vitor Sousa, October 2024

  4. PROVEO coordination that runs on data, not meetings

    The PROVEO alliance with AGC Biologics and Oncotec coordinates mAb, linker, payload and conjugate production through manual project management; upstream delays are visible only at scheduled reviews, leaving little time to adjust bioconjugation schedules.

    A controlled, role-limited view of mAb, linker, payload and conjugate production across the three companies turns the alliance into a real-time-visibility offer rather than a one-stop-shop that runs on calls, and gives the bioconjugation team the lead time to replan.

    • Restructured Proveo one-stop-shop for ADCs — Cerbios-Pharma SA
    • Cerbios-Pharma SA, 247 Biopharma Interview with Vitor Sousa, October 2024

  5. Per-batch energy and carbon footprint data

    A 525 kWp photovoltaic system at Lugano covers around ten percent of site energy, but the remaining ninety percent comes from the grid with no per-batch linkage, and Big Pharma Scope 3 reporting is asking for that level of detail.

    Joining the photovoltaic telemetry with shop-floor power draw lets each batch carry its own energy and carbon figure, and lets energy-intensive steps be scheduled around the solar window without disturbing release timing.

    • Cerbios-Pharma SA, Sustainability Report, September 2025
    • Cerbios-Pharma SA, Sustainability

What we'd propose

  • Digital CDMO

    Non-intrusive process instrumentation for Category 4 containment

    Retrofit HPAPI reactors, nanofiltration and freeze-drying units in SafeBridge Category 4 isolators with OPC UA sensors and a streaming pipeline, so pressure, temperature and flow values leave the equipment in a documented, vendor-neutral form while the isolator stays sealed.

    • OPC UA on existing Category 4 units

      Data off the equipment, glass intact

      Add OPC UA-enabled sensors to HPAPI reactors, nanofiltration and freeze-drying skids so process values leave the unit in a documented, vendor-neutral form, with no physical penetration of the isolator envelope.

    • Real-time deviation alerts at the control room

      Alerts before the batch finishes

      Build the normal operating envelope for each critical parameter from historical runs, then flag drift to operators outside the containment zone while the batch is still running, so a deviation is seen at the line rather than reconstructed afterwards.

    • Per-batch process record assembled as you go

      Evidence produced by the line

      Stream monitored parameters straight into a per-batch record with lineage back to the instrument that produced each value, so the release evidence is generated continuously and stands up to inspection without manual assembly.

    • Operators see a deviation while the batch is still on the line, not in a later report.
    • Data leaves the isolator without breaking containment, so the 20-year inspection posture is preserved.
    • Release evidence carries its own lineage back to the instrument that produced it.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Ontology-based group data platform for the HAS Group

    Build a shared data architecture that defines capacity, batch, lot, equipment and quality event as common entities across Lugano, Couvet and Biasca, and loads each site's ERP and LIMS output against that model so group-level reporting becomes a query rather than a reconciliation.

    • Shared manufacturing ontology across three sites

      One agreed set of entities

      Define capacity, batch, lot, equipment and quality event as explicit entities with agreed relationships, so a question written once returns the same answer from each site instead of three dialects of the same table.

    • Connectors for legacy ERP and LIMS

      Loading without replacement

      Build ingestion for the existing ERP and LIMS estates at Lugano, Couvet and Biasca with schema validation at the boundary, so each site's data enters the platform in a form that can be queried without replacing the underlying systems.

    • Executive KPI dashboard for group-level decisions

      Numbers 65 Equity Partners can read

      Expose group-level capacity utilisation, batch success rates and financial performance through a dashboard that the CEO/CFO and the investor side can read directly, so ROI reporting stops being a per-cycle extract.

    • Group-level reporting becomes a query on a shared model, not a per-site extract.
    • Each site's existing systems stay in place; integration happens at the data layer.
    • Capacity and ROI reporting reach the investor side on a single timeline.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    ADC analytical data layer for the R&D and QC laboratories

    Connect the NMR, HR-Q-TOF, DSC and UPLC instruments into one analytical data layer with a shared ontology for sample, method and result, so ADC characterisation packages are assembled from the data instead of typed into a document.

    • Automated ingestion from analytical instruments

      Results captured at the instrument

      Connect the 400 MHz NMR, HR-Q-TOF mass spectrometer, DSC and UPLC systems so results are captured with instrument identity, method version and timestamp attached, instead of being read off a screen and typed into a spreadsheet.

    • Sample and result ontology

      Same name for the same thing

      Map sample, method, run, result and lot as shared entities so results from different instruments about the same batch line up automatically, and a regulatory package pulls the right numbers without per-instrument reconciliation.

    • Release package assembly from data

      Documents generated, not transcribed

      Generate the regulatory package for an ADC batch from validated analytical data with full ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring and Available) audit trail, so the scientist's role moves from transcription to review.

    • Scientist time returns to interpretation rather than data formatting.
    • A regulatory package is assembled from the data with its own audit trail.
    • New payloads and linkers enter through the same data flow instead of a new manual path.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    PROVEO cross-company production visibility

    Stand up a controlled, role-limited view of mAb, linker, payload and conjugate production status across Cerbios, AGC Biologics and Oncotec, so the alliance can be sold on real-time visibility rather than on scheduled meetings.

    • Cross-partner API integration

      Encrypted feeds between three companies

      Establish controlled data feeds from AGC Biologics mAb production and Oncotec fill and finish operations, with role-based access so each partner sees only the data its role requires.

    • Production timeline visualisation

      One view of mAb, linker, payload, conjugate

      Build a dashboard that shows the live status of each component against the planned schedule, with milestone notifications so a delay is visible at the moment it happens and not at the next review.

    • Schedule adjustment lead time

      More time to replan bioconjugation

      Surface upstream delays early enough that the bioconjugation team can adjust capacity and timing, turning reactive schedule repair into a planned activity with documented rationale.

    • PROVEO is sold on real-time visibility rather than on coordinated meetings.
    • Each partner controls what the others see through role-based access.
    • Upstream delays reach bioconjugation early enough to plan around them.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Per-batch energy and carbon reporting for sustainability premium

    Join the Lugano 525 kWp photovoltaic telemetry with shop-floor power draw so each batch carries its own energy source mix and carbon figure, and energy-intensive steps can be scheduled against the solar window without disturbing release timing.

    • Solar-to-process correlation

      Energy source per batch

      Connect the photovoltaic system output with the manufacturing execution system so each batch records what share of its energy came from the on-site solar plant and what share came from the grid.

    • Energy-aware scheduling

      Heavy steps in the solar window

      Schedule chromatography, freeze-drying and sterilisation cycles to coincide with peak photovoltaic output where it does not extend batch release dates, so energy cost and grid load drop without disturbing throughput.

    • Automated Scope 3 reporting

      Per-batch carbon figures

      Generate per-batch carbon footprint figures and roll them up into the September 2025 Sustainability Report so Big Pharma customers receive the granular Scope 3 information their own reporting now expects.

    • Each batch carries its own energy source mix and carbon figure.
    • Energy-heavy steps move into the solar window without disturbing release timing.
    • Scope 3 reporting reaches Big Pharma customers with the granularity they now require.

    We've done this before

    See how we do Digital CDMO

Where QB Systems fits

Alongside our services we build QB Systems, hardware and software for bioprocess control. QB Systems is a product brand of A4BEE Sp. z o.o.

Applications
Bioreactors

Software-defined control for a bioreactor — a new QB vessel, an upgrade to one you have, or a retrofit of the existing PLC.

Filtration (TFF)

Benchtop tangential flow filtration for concentration, diafiltration and buffer exchange.

Automated sampling

Automated sampling from 4–18 sources, aseptic-capable and up to 72 hours unattended. Works with any vendor's bioreactor.

Deployment
Retrofit

Existing equipment keeps running; QB takes over the PLC, or reads from it without touching control.

Scale
Pilot (50–300 L)

Stainless steel, where QB supplies the control software and integration and a certified partner builds the installation.

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Cerbios-Pharma SA's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 35 → 80
Three sites run on separate ERP and LIMS estates and group-level reporting is built from per-site extracts; the Investments Plan 2026 frames the shared data architecture as a 2026 priority rather than as work already in place.
Process automation 45 → 85
Category 4 containment forces manual data capture inside the isolator and PROVEO coordination runs through project management; the technical case for automation is established, with the work scoped and resourced under the Investments Plan 2026.
Analytics and AI 30 → 75
ADC characterisation today is manual compilation across NMR, HR-Q-TOF, DSC and UPLC; AI-assisted heterogeneity analysis is a recognised direction but not yet embedded in the routine release path.
IT/OT convergence 40 → 80
R&D was brought inside operations under the 2019 organisational change, but process development still relies on human troubleshooting rather than on a digital twin of the production line.
Regulatory technology 50 → 85
The 20-year inspection record across FDA, Swissmedic, PMDA and EMA is maintained by a strong QA and Qualified Person team; the same standard at the larger post-acquisition volume calls for ALCOA+ evidence generated by systems rather than assembled by hand.
Sustainability intelligence 35 → 75
The 525 kWp photovoltaic installation covers around ten percent of Lugano's energy and is the first site-level measurement; per-batch energy and Scope 3 reporting is the gap that Big Pharma customers are now asking to close.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Cerbios-Pharma SA, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].